Video

Dr. Girard on Maximizing Outcomes of Lung Cancer Treatments

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).

Girard begins by stating that using crizitonib in the first-line setting is an effective way to produce positive results when treated for ALK-positive NSCLC. Crizotinib is also accessible as a second-line treatment, but the progression-free survival (PFS) is lower at an estimated 8 months.

Girard discusses that it is important to understand and identify progressive disease that can develop with patients using crizotinib. This can occur in 1 or 2 tumors but can be managed with a low-calibrated treatment and a continuation of crizotinib. By doing this, the duration of treatment, as well as the benefits, are increased.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.